Postremission Therapy With Actinium-225 (225Ac)-Lintuzumab (Actimab-A®) in Patients With Acute Myeloid Leukemia
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2019
At a glance
- Drugs Lintuzumab (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 07 Feb 2019 Last checked against ClinicalTrials.gov: US National Institutes of Health
- 31 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 1 Mar 2019.
- 10 Oct 2018 Status changed from planning to not yet recruiting.